Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...

Supernus Pharmaceuticals (NASDAQ:SUPN) stock received a price target increase from TD Cowen, with the target moving up to $44.00 from the previous $43.00. The firm maintained a Buy rating on the ...

Several Kentucky bills filed this legislative session have one thing in common: a shared skepticism of guidance from top U.S.

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an acquisition target. During his discussion, Holz suggested that Viking could ...

The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...